[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"CCRF Inc., Beijing, China\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100435008","to-evaluate-whether-ivus-guided-drug-eluting-stent-des-implantation-leads-to-better-clinical-outcomes-compared-to-conventional-angiography-in-the-treatment-of-chronic-complete-occlusion-cto-disease-100435008",false,"NCT04944615","To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease.","IVUS-CTO: Comparison of the Effect of Intravascular Ultrasound-guided Versus Angiographic-guided Drug-eluting Stent Implantation on Long-term Clinical Outcomes in Patients With Chronic Complete Occlusion of Coronary Artery Disease: a Prospective, Multicenter, Randomized Controlled Clinical Study","CRUISE-CTO","Clinical inclusion criteria:\n\n1. At least 18 years old\n2. Subjects will understand the test requirements, treatment and surgery, and can provide written informed consent\n3. Subjects with clinical symptoms of ischemic heart disease or evidence of myocardial ischemia associated with CTO target vessels and scheduled to undergo Percutaneous coronary intervention (PCI)\n4. Subjects will receive percutaneous coronary intervention\n5. Subjects are willing to accept all treatment and follow-up evaluations required by the protocol\n\nInclusion criteria for angiography:\n\n1. Primary coronary artery CTO lesion with visible collateral circulation\n2. Estimation of the time to complete occlusion (TIMI grade 0) ≥3 months based on clinical history and\u002For comparison with historical angiography or ECG\n3. It is suitable for target lesions of 2.25-4.0mm stent implantation\n4. The length of CTO lesion should be greater than 20mm\n\nClinical exclusion criteria:\n\n1. Pregnant and lactating women\n2. Severe coronary artery disease, not suitable for PCI\n3. Patients with acute myocardial infarction less than 7 days\n4. Long-term contraindications to DAPT (at least 1 year)\n5. Known renal insufficiency.20 mL\u002Fmin \u002F 1.73 ㎡)\n6. Left ventricular ejection fraction \\<35% or cardiogenic shock\n7. The ICD implanted\u002FCRT\n8. Severe bleeding or stroke within 6 months\n9. Have a history of allergy to iodine contrast agents or any known allergy to clopidogrel, ticagrelor, aspirin, or heparin\n10. Subjects have been diagnosed or suspected of liver disease, including laboratory evidence of hepatitis\n11. Valvular heart disease significantly affecting hemodynamics, hypertrophic cardiomyopathy, restrictive cardiomyopathy, or congenital heart disease\n12. Diseases that researchers believe may seriously harm patients, such as cancer and mental illness;Or the patient's life expectancy is less than one year and the follow-up cannot be completed;Or other conditions that researchers think might have confounded the results\n13. Participate in any other ongoing trial or intend to participate in another clinical trial of a drug or device within 12 months after baseline surgery\n\nAngiographic exclusion criteria:\n\n1. The target lesion is located in the left main artery\n2. No visible collateral circulation in CTO lesions\n3. Target lesion is venous or arterial bypass graft\n4. The target vessel occlusion time (TIMI grade 0) \\\u003C 3 months can be determined","ALL","18 Years",{"count":20,"type":21},1448,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to evaluate the treatment of Chronic total occlusion (CTO) disease. Whether Intravascular Ultrasonography (IVUS) guiding the implantation of drug-eluting stents (DES) will provide better long-term clinical outcomes compared with conventional angiography",[27],"Chronic Total Occlusion of Coronary Artery",[29],"TIMI flow = grade 0 coronary artery disease with a duration greater than 3 months.","RECRUITING","2023-03-27",{"date":33,"type":34},"2023-03-29","ACTUAL",{"date":36,"type":34},"2022-10-21",{"date":38,"type":21},"2031-10",{"name":40,"class":41},"CCRF Inc., Beijing, China","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":4},"100438358","multi-center-registry-of-transcatheter-aortic-valve-replacement-in-northeast-china-100438358","NCT04988243","Multi Center Registry of Transcatheter Aortic Valve Replacement in Northeast China","Inclusion Criteria:\n\n1. Severe aortic valve stenosis, defined as follows:\n\n   1. Symptomatic patients:\n\n      * The mean differential pressure measured by echocardiography ≥ 40mm Hg\n      * Or peak aortic ejection ≥ 4.0 m \u002F S\n      * Or aortic valve area ≤ 1.0cm ²（ Or AVA index ≤ 0.6 cm2 \u002F m2)\n   2. Asymptomatic patients:\n\n      * Severe aortic stenosis and aortic valve area ≤ 1.0cm ²（ 6 cm2 \u002F m2) with aortic ejection peak value ≥ 5.0 M \u002F s or mean pressure difference measured by --echocardiography ≥ 60 mm Hg;\n      * Or aortic valve area ≤ 1.0cm ²（ Or AVA index ≤ 0.6 cm2 \u002F m2), combined with aortic ejection peak ≥ 4.0 m \u002F s or average differential pressure measured by echocardiography ≥ 40 mm Hg, combined with limited exercise tolerance test, abnormal blood pressure response or arrhythmia;\n      * Or aortic valve area ≤ 1.0cm ²（ Or AVA index ≤ 0.6 cm2 \u002F m2), combined with aortic ejection peak ≥ 4.0 m \u002F s or average differential pressure measured by echocardiography ≥ 40 mm Hg, combined with LVEF \\\u003C 50%\n2. Subjects who plan (or have) to use the transcatheter aortic valve replacement system for percutaneous aortic valve replacement\n3. The patients agreed to join the study, voluntarily signed the informed consent and completed the follow-up;\n4. Be able to contact the subjects or their legal guardians \u002F relatives;\n5. The medical record records the subjects who have died and can't get any contact information of the subjects（ (for dead cases only)\n\nNote: for dead subjects, they must meet 1, 2 and 5 at the same time before they can be included in the group.\n\nExclusion Criteria:\n\n1. Contraindications to any artificial biological valve implantation;\n2. Any known allergies or contraindications;\n\n   * Aspirin or heparin and bivalirudin;\n   * Tigrelol and clopidogrel;\n   * Nickel titanium alloy;\n   * Contrast medium;\n3. The patient is currently participating in drug or device research;\n4. The patient is pregnant or lactating;\n5. Aortic annulus diameter \\\u003C 17 mm or \\> 32 mm;\n6. The diameter of approach vessel was less than 5.0mm;\n7. The investigator believes that the patient is not suitable to participate in this study or complete the follow-up specified in the protocol;",{"count":50,"type":21},320,[24],"The purpose of this study was to observe the safety and effectiveness of transcatheter aortic valve replacement in patients with aortic valve stenosis in a real-world clinical practice environment.",[54],"Severe Aortic Valve Stenosis","NOT_YET_RECRUITING","2021-08-01",{"date":58,"type":34},"2021-08-03",{"date":60,"type":21},"2021-08",{"date":62,"type":21},"2028-08",{"name":40,"class":41},""]